Treatment Strategies with Elranatamab in R/R MM: Updates from the MagnetisMM Trials
Naresh Bumma, MD, and Hans Lee, MD, recap recent updates on the MagnetisMM-30 an MagnetisMM-32 studies investigating elranatamab, a BCMA-directed bispecific antibody.
EP: 1.Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study
EP: 2.Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights
EP: 3.Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM
EP: 4.Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1
Now Viewing
EP: 5.Treatment Strategies with Elranatamab in R/R MM: Updates from the MagnetisMM Trials
EP: 6.Expert Perspectives: Sequencing Approaches with CAR-T and Bispecifics in R/R MM
EP: 7.Expert Insights: Strategies for Step-Up Dosing and Long-Term Treatment Management with Bispecifics in R/R MM
EP: 8.The Role of MRD Testing in Guiding Treatment in R/R MM: ASCO 2024 Updates from PERSEUS
EP: 9.Considerations in Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in R/R MM
EP: 10.Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials
EP: 11.AE Management for CAR-T Therapy: Expert Insights and Perspectives
EP: 12.Looking Ahead: ASCO 2024 Updates and Future Perspectives
EP: 13.Key Takeaways and Clinical Pearls on the Treatment of R/R MM in the Era of Bispecifics
EP: 14.Bispecific Antibodies Are Taking the Multiple Myeloma World by Storm
Video content above is prompted by the following question:
- Please comment on the recent updates from MagnetisMM-30 evaluating elranatamab with iberdomide.
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
